Catalyst

Slingshot members are tracking this event:

Takeda Receives Positive CHMP Opinion for ADCETRIS (brentuximab vedotin) as Consolidation Treatment in Post-Transplant Hodgkin Lymphoma

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
TKPYY

100%
Slingshot Insights Explained
Catalyst Date
Occurred on:
May 27, 2016
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Brentuximab Vedotin, Post-transplant Hodgkin Lymphoma, Adcetris